Skip to Main Content

Advertisement

Skip Nav Destination

Mathias Rummel, MD, PhD: Bendamustine-Rituximab "StiL" Beats R-CHOP for Indolent Lymphomas

December 30, 2021
On location

Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with indolent lymphomas.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement